Lexicon Pharmaceuticals | LXRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 11.66B 1.2B 2026-09
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
AstraZeneca USD 11.55B 674M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 198M 4.66M 2026-09
Illumina USD 525M 374M 2026-09
Insmed USD 606.26M 79.46M 2026-09
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 18.93B 1.09B 2026-09
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 42.87M 21.68M 2026-06
MannKind USD 104.44M 5.77M 2026-09
Merck USD 10.75B 5.02B 2026-09
Moderna USD 1.18B 223M 2026-09
Novartis USD 9.88B 325M 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Thermo Fisher Scientific USD 9.68B 134M 2026-09
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
United Therapeutics USD 6.28B 124.3M 2026-09
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12